Siddik ZH[au] - Search Results

Year	Number of Results
1975	1
1979	7
1980	6
1981	1
1982	3
1983	2
1984	1
1985	2
1986	2
1987	6
1988	7
1989	6
1990	4
1991	5
1992	5
1993	9
1994	14
1995	2
1996	2
1997	3
1998	4
1999	4
2000	2
2001	1
2002	1
2003	5
2004	1
2005	3
2006	1
2007	1
2008	1
2009	3
2010	2
2011	4
2012	3
2013	4
2014	2
2015	2
2016	3
2017	4
2018	1
2019	3
2020	4
2021	2

1

Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights.

Farooqi AA, de la Roche M, Djamgoz MBA, Siddik ZH. Farooqi AA, et al. Among authors: siddik zh. Semin Cancer Biol. 2019 Oct;58:65-79. doi: 10.1016/j.semcancer.2019.01.001. Epub 2019 Jan 8. Semin Cancer Biol. 2019. PMID: 30633978 Review.

2

Cisplatin: mode of cytotoxic action and molecular basis of resistance.

Siddik ZH. Siddik ZH. Oncogene. 2003 Oct 20;22(47):7265-79. doi: 10.1038/sj.onc.1206933. Oncogene. 2003. PMID: 14576837 Review.

3

Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.

Hong B, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y, Selvendiran K, Pei G, Zhao Z, Yoo JY, Kaur B. Hong B, et al. Among authors: siddik zh. Clin Cancer Res. 2021 Jan 15;27(2):542-553. doi: 10.1158/1078-0432.CCR-20-2210. Epub 2020 Oct 21. Clin Cancer Res. 2021. PMID: 33087329

4

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. Rodriguez-Aguayo C, et al. Among authors: siddik zh. EBioMedicine. 2019 Feb;40:290-304. doi: 10.1016/j.ebiom.2018.11.045. Epub 2019 Jan 14. EBioMedicine. 2019. PMID: 30655206 Free PMC article.

5

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Calvert AH, et al. Among authors: siddik zh. J Clin Oncol. 1989 Nov;7(11):1748-56. doi: 10.1200/JCO.1989.7.11.1748. J Clin Oncol. 1989. PMID: 2681557

6

Platinum(IV)-Ferrocene Conjugates and Their Cyclodextrin Host-Guest Complexes.

Thiabaud G, Harden-Bull L, Ghang YJ, Sen S, Chi X, Bachman JL, Lynch VM, Siddik ZH, Sessler JL. Thiabaud G, et al. Among authors: siddik zh. Inorg Chem. 2019 Jun 17;58(12):7886-7894. doi: 10.1021/acs.inorgchem.9b00570. Epub 2019 May 24. Inorg Chem. 2019. PMID: 31125214 Free PMC article.

7

Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents.

Thiabaud G, He G, Sen S, Shelton KA, Baze WB, Segura L, Alaniz J, Munoz Macias R, Lyness G, Watts AB, Kim HM, Lee H, Cho MY, Hong KS, Finch R, Siddik ZH, Arambula JF, Sessler JL. Thiabaud G, et al. Among authors: siddik zh. Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7021-7029. doi: 10.1073/pnas.1914911117. Epub 2020 Mar 16. Proc Natl Acad Sci U S A. 2020. PMID: 32179677 Free PMC article.

8

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. Moreno-Smith M, et al. Among authors: siddik zh. J Clin Invest. 2018 Jul 2;128(7):3199. doi: 10.1172/JCI122301. Epub 2018 May 29. J Clin Invest. 2018. PMID: 29809169 Free PMC article. No abstract available.

9

Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.

He G, Xie X, Siddik ZH. He G, et al. Among authors: siddik zh. Cancer Chemother Pharmacol. 2020 Jun;85(6):1129-1140. doi: 10.1007/s00280-020-04085-1. Epub 2020 May 28. Cancer Chemother Pharmacol. 2020. PMID: 32468080

10

Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.

Xie X, He G, Siddik ZH. Xie X, et al. Among authors: siddik zh. Mol Pharmacol. 2020 Apr;97(4):237-249. doi: 10.1124/mol.119.117564. Epub 2020 Feb 16. Mol Pharmacol. 2020. PMID: 32063580 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results